BillionToOne, Inc. (BLLN)
| Market Cap | 4.40B |
| Revenue (ttm) | 397.41M +90.1% |
| Net Income | 33.18M |
| EPS | 0.77 |
| Shares Out | 47.19M |
| PE Ratio | 121.25 |
| Forward PE | 115.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423,070 |
| Open | 94.90 |
| Previous Close | 95.15 |
| Day's Range | 92.58 - 95.90 |
| 52-Week Range | 61.96 - 150.44 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 119.71 (+28.39%) |
| Earnings Date | Aug 5, 2026 |
About BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 8 analysts, the average rating for BLLN stock is "Buy." The 12-month stock price target is $119.71, which is an increase of 28.39% from the latest price.
News
BillionToOne announces publication of study on cfDNA fetal risk assessment
BillionToOne (BLLN) announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green...
Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions
Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results ME...
BillionToOne falls -38.3%
BillionToOne (BLLN) is down -38.3%, or -$57.46 to $92.51.
BillionToOne falls -36.7%
BillionToOne (BLLN) is down -36.7%, or -$54.97 to $95.00.
BillionToOne price target lowered to $130 from $145 at JPMorgan
JPMorgan analyst Casey Woodring lowered the firm’s price target on BillionToOne (BLLN) to $130 from $145 and keeps an Overweight rating on the shares. The company reported a “bit of…
BillionToOne price target lowered to $130 from $142 at BTIG
BTIG lowered the firm’s price target on BillionToOne (BLLN) to $130 from $142 and keeps a Buy rating on the shares. Shares declined after an in-line quarter impacted by one-time…
BillionToOne reports Q2 EPS 15c, consensus 16c
Reports Q2 revenue $109.45M, consensus $109.12M. “Our second quarter demonstrated the durability of our model, with our differentiated technology platform, category-defining products, and disciplined ...
BillionToOne backs FY26 revenue view $450M-$465M, consensus $454.14M
The company said, “BillionToOne (BLLN) continues to expect full year 2026 total revenue of $450.0 million to $465.0 million, representing growth of 48% to 52% compared to full year 2025.
BillionToOne Earnings Call Transcript: Q2 2026
Q2 2026 saw 64% year-over-year revenue growth to $109.4 million, with gross margin above 70% and strong gains in both prenatal and oncology. New product launches, rapid health system integrations, and robust cash flow position the company for continued growth and profitability.
BillionToOne Slides: Q2 2026
BillionToOne has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 5, 2026.
BillionToOne Earnings release: Q2 2026
BillionToOne released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
BillionToOne Quarterly report: Q2 2026
BillionToOne has published its Q2 2026 quarterly earnings report on August 5, 2026.
BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance
MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne appoints Ethan Dmitrovsky as Chief Medical Officer
BillionToOne (BLLN) announced the appointment of Ethan Dmitrovsky, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology. Dmitrovsky will lead ...
BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar
Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding ...
BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026
MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are a...
BillionToOne's Northstar Response® Is a Stronger Predictor of Immunotherapy Outcomes Than Standard-of-Care Imaging for Cancer Patients in Peer-Reviewed Study
Tissue-free ctDNA monitoring was the dominant independent predictor of survival across 12 tumor types and two prospective cohorts MENLO PARK, Calif., June 29, 2026 /PRNewswire/ -- BillionToOne, Inc. (...
BillionToOne price target raised to $125 from $120 at Guggenheim
Guggenheim raised the firm’s price target on BillionToOne (BLLN) to $125 from $120 and keeps a Buy rating on the shares. The firm adjusted models and forecasts for select companies…
BillionToOne Transcript: AGM 2026
The meeting confirmed quorum, elected two directors for terms ending in 2029, and ratified the appointment of the independent auditor for 2026. Stockholders were invited to participate in a Q&A session after formal business concluded.
BillionToOne Transcript: 46th Annual William Blair Growth Stock Conference
Patented single molecule diagnostics technology has driven exponential revenue growth, high gross margins, and GAAP profitability. Category-defining products in prenatal and oncology have changed medical guidelines and treatment paradigms, with ongoing innovation and ambitious growth targets.
BillionToOne to Participate in the William Blair 46th Annual Growth Stock Conference
MENLO PARK, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are ac...
BillionToOne price target raised to $120 from $100 at Guggenheim
Guggenheim raised the firm’s price target on BillionToOne (BLLN) to $120 from $100 and keeps a Buy rating on the shares after having hosted management for a series of investor…
BillionToOne price target raised to $125 from $120 at JPMorgan
JPMorgan analyst Casey Woodring raised the firm’s price target on BillionToOne (BLLN) to $125 from $120 and keeps an Overweight rating on the shares.
BillionToOne price target lowered to $130 from $140 at BTIG
BTIG lowered the firm’s price target on BillionToOne (BLLN) to $130 from $140 and keeps a Buy rating on the shares.
BillionToOne sees FY26 revenue $450M-$465M, consensus $437.6M
Expects to operate the business such that it will continue to generate profitability approaching current levels, even with significant continued investments.